{
    "nctId": "NCT03831711",
    "briefTitle": "68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer",
    "officialTitle": "A Pilot Study of 68-Ga-RM2 PET/MRI in the Evaluation of Patients With Estrogen Receptor-Positive Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Carcinoma, Estrogen Receptor Positive",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 5,
    "primaryOutcomeMeasure": "Detection of ER Positive Breast Cancer and Metastases on 68-Ga RM2 PET/MRI",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* ER+ breast cancer at initial diagnosis prior to surgery or at recurrence (at least one ER+ lesion based on results of biopsy).\n* Able to provide written consent\n* Karnofsky performance status of \u2265 50 (or Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) equivalent)\n\nExclusion Criteria:\n\n* Less than 18 years-old at the time of radiotracer administration\n* Inability to lie still for the entire imaging time\n* Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)\n* Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance\n* Renal function impairment preventing administration of MRI contrast\n* Metallic implants (contraindicated for MRI)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}